StockWatch
·

Omnitech Engineering Ltd Q1 FY27 Results

OMNIQ1 FY27 Results
Filing
Result:Very Good· Market: SurgedBase effectOne-off gainMargin squeeze

Outlook: Optimistic · Guidance: Raised

MetricValuevs Q4 FY26
Revenue166.66 Cr12.1%
Total Income172.44 Cr7.2%
Expenditure132.75 Cr8.6%
PBT39.68 Cr2.8%
Net Profit29.73 Cr1.4%
OPM30.37%3.09pp
NPM17.24%1.00pp
EPS2.409.4%
View full financials

Revenue growth of 61.5% YoY beat management's own 30-35% guidance, but the YoY comparison is against a depressed, unaudited first-listed-quarter base, ~₹7.6 Cr of the PBT beat came from a one-time depreciation-method change rather than the core business, and OPM/NPM both compressed QoQ (30.37%→33.46%, 17.24%→18.24%) against management's expectation of margin reversion — solid core growth but not top-tier quality.

OMNITECH ENGINEERING · Q1 FY27 · THE VERDICT

The 61% Growth That Masks a Slower, Margin-Squeezed Organic Story

Omnitech's Q1 reported 61.5% YoY revenue growth and a 30.4% EBITDA margin, but the comparison is inflated by a weak prior-year base. Quarter-on-quarter momentum is softer: revenue up 12%, PAT up just 1.4%. The market's -14% selloff reflects justified skepticism about organic profitability.

10 Aug 2026 · 6 min read
Reported YoY growth

+61.5%

Revenue ₹166.7 Cr | PAT ₹29.7 Cr

Organic QoQ growth

+12.1% rev | +1.4% PAT

Margin compression ~90 bps

Market reaction (day 1)

-14.41%

₹732.6 → ₹578.35

The headline is a distraction. Omnitech's 61.5% YoY revenue growth and 468.7% PAT surge look exceptional on paper, but both metrics are inflated by a deeply depressed prior-year base: Q1 FY26 coincided with the Chhapara facility ramp-up and heavy pre-emptive investment. The real earnings story is the quarter-on-quarter momentum: revenue growing 12.1% while PAT crawled forward just 1.4%. That margin compression — roughly 90 basis points — is the tension that defines the quarter and explains why the market punished the stock 14% despite what looked like blowout numbers.

What the divergence reveals: raw material lag is biting

Management claimed "100% raw material and forex pass-through" to customers, but the P&L tells a different story. Cost of goods sold, as a percentage of revenue, rose sequentially: 20% (Q3 FY26) → 24% (Q4) → 28% (Q1 FY27). That 8-percentage-point drift in a single quarter is material. On the call, management acknowledged the lag explicitly: raw material cost increases take 2–3 months to flow through to customers via quarterly business reviews (QBRs). In the interim, Omnitech absorbs the margin hit. This is not a crisis — long-term contracts and pass-through clauses are real — but it explains why PAT growth (1.4% QoQ) lags revenue growth (12.1%). The gap will narrow as price increases propagate, but near-term earnings are volatile.

Management claims vs. what the numbers support

61.5% YoY revenue growth, PAT surged

What the data shows

₹166.7 Cr revenue, ₹29.7 Cr PAT, but QoQ only +12.1% rev and +1.4% PAT

Verdict

Supported (headline), but prior year was depressed; organic growth is slower

35–40% FY27–FY28 guidance (raised from 30–35%)

What the data shows

Q1 was 61.5% YoY vs. weak base; full-year guided 35–40%, implying moderation

Verdict

Supported; guidance raised but modestly; normalized run-rate ~35–40%

Robust ₹3,000 Cr order book, 3–5 year visibility

What the data shows

Confirmed: ₹2,000 Cr multi-year oil/gas (3–5 yr), ₹1,000 Cr short/medium (6–18 mo)

Verdict

Supported, but 67% concentrated in two anchors (oil/gas)

100% raw material and forex pass-through

What the data shows

COGS % rose 20%→28% QoQ; 2–3 month lag acknowledged; currency pass-through also lagged

Verdict

Overstated; true long-term but operationally misleading short-term

Working capital improved meaningfully to 233 days from 294

What the data shows

Confirmed: inventory 225→182 days, receivables 153→119, payables 80→69

Verdict

Supported; execution solid; target further 10–20% improvement

What changed on this call

  • Growth guidance raised 30–35% → 35–40% (modest upgrade for FY27–FY28)

  • Capex accelerated: ₹250 Cr over 14 months (₹100 Cr building, ₹150 Cr plant/machinery)

  • Machine capacity +30% (42–43 lakh hours post-ramp); FY28 commissioning

  • Defense/aerospace now in first-article (FA) and Nadcap certification phases; 1–3 year ramp

  • Working capital discipline demonstrated: 61-day improvement; further 10–20% target

  • Margin outlook stable, not expanding: EBITDA 30%+, gross 68–71%, reflecting raw material lag

Bull-bear ledger
  • Order book visibility: ₹3,000 Cr, 3–5 years out, anchored by Weatherford and oil/gas majors

  • Capex-backed capacity adds 30% machine hours; targets ₹1,600+ Cr revenue potential post-ramp

  • Working capital discipline: 61-day improvement YoY, target further 10–20% (cash generation tailwind)

  • Geographic diversification underway: North America 52% rebalancing toward Europe/Middle East (10–20% target)

  • Q1 headline 61% growth is inflated by depressed prior-year base; organic QoQ momentum is slower (12% rev, 1.4% PAT)

  • Raw material cost lag (2–3 months) is squeezing margins QoQ; COGS % rose 20%→28% despite pass-through claims

  • Customer concentration: ₹2,000 Cr of ₹3,000 Cr (67%) in two oil/gas anchors; trials with 3–4 majors underway (6–12 mo timeline)

  • Capex execution delayed (1–1.5 months behind schedule due to rains); utilization ramp unproven

  • Defense/aerospace entry is speculative: <1% of revenue, 1–3 year ramp, no quantified order pipeline

Risks, ranked by holder concern

What can derail the story

Customer concentration (₹2,000 Cr / ₹3,000 Cr = 67% in two oil/gas anchors)

High

Weatherford + one unnamed large customer dominate the order book. Loss of either (e.g., cyclical pullback, competitive loss) would materially compress revenue visibility. Mitigation: trials with ABB, Siemens, Oshkosh, BLY underway; 6–12 month approval timeline.

Raw material cost lag (2–3 months pass-through via QBRs)

High

COGS % of revenue rose 20%→28% QoQ despite claimed 100% pass-through. This creates quarterly earnings volatility and margin compression until customers reprice. Mitigation: long-term contracts with pass-through clauses; currency hedges in place; lag should normalize over time.

Capex execution and utilization (₹250 Cr for +30% capacity)

Medium

New facilities start FY28, already 1–1.5 months behind schedule. If order book doesn't grow proportionally, utilization and ROCE could suffer. Mitigation: ₹3,000 Cr order book provides buffer; management disciplined on capex pacing; phased machinery deployment.

Defense/aerospace ramp timing (1–3 years, currently <1% revenue)

Medium

Entry is real (FA approvals, Nadcap certification in progress), but revenue contribution is speculative. Framed as 'very good vertical' but no quantified order pipeline or timeline. Mitigation: multiple Tier-1 OEM trials ongoing; capability already exists (precision to 5 microns).

Geographic concentration (North America 52%, oil/gas exposed)

Medium

Downturn in US shale/energy cycle could compress order flow and utilization. Rebalancing to Europe/Middle East is underway (10–20% target) but slow. Mitigation: broad customer base (256+ customers across 24 countries); emerging regions growing.

How the street is positioned

The market's -14.41% sell-off on day 1 (₹732.6 → ₹578.35) is the street's own verdict on earnings quality. Stock is now 24% below its all-time high of ₹762.7 but still +228% above the 52-week low of ₹176.25, reflecting the prior run-up from the IPO narrative. Critically, institutional positioning is stable: FII ownership flat at 4.31% (up 5 bps), DII trimmed to 10.81% (down 112 bps), promoter steady at 74.19%. The lack of panic FII selling suggests large institutions are not bailing, but the retail/momentum crowd clearly took the headline-misses-organic-growth signal and exited. Volume is increasing, a sign of distribution. The stock's trend remains bullish on the longer chart, but the sharp post-result selloff shows the market is rightfully skeptical: a quarter that looked great in headlines but shows margin compression and slowing organic momentum is not worth holding at an all-time-high valuation.

What to watch next
  • 1 · Q2 QoQ growth trajectory

    Does revenue growth accelerate or plateau? Critically, does PAT grow faster than the 1.4% QoQ pace? If margin compression persists, it signals the raw material lag is not normalizing. Watch for any commentary on pricing resets or contract renewals.

  • 2 · Capex ramp and new facility commissioning (H1 FY28)

    Does Chhapara's new facility come online on time (already 1–1.5 months delayed)? What are the first-quarter utilization rates? Hitting 35–40% full-year growth guidance will require the new capacity to absorb incremental demand. Miss here and ROCE assumptions crumble.

  • 3 · Customer diversification trials (6–12 month cycle)

    Do the motion-control/automation trials with ABB, Siemens, Oshkosh, BLY convert to orders? This is the key to de-risking the oil/gas concentration (67% of order book). If large assembly-side orders win approvals, incremental revenue and margin expansion could follow.

  • 4 · Defense/aerospace FA approvals and Nadcap progress

    Any material order wins or customer commitments? This vertical is speculative today but could be a needle-mover if 1–3 year ramp accelerates faster than guided.

Omnitech is a solid execution story with real scaffolding: an order book, disciplined capex, and emerging high-margin verticals. But this quarter is a reminder that headlines can mask softer organic momentum. A 61% YoY surge built on a depressed prior base, paired with a 1.4% QoQ PAT growth, is not the picture of acceleration. Raw material cost lag is squeezing margins today, and until the 2–3 month pass-through cycle normalizes, earnings will remain volatile. The market's 14% selloff is justified.

For holders, the question is whether the order book and capex ramp justify near-term margin pressure. For entry points, wait for evidence that organic QoQ growth is re-accelerating and margin pressure is lifting. The number to track is quarterly PAT growth, not revenue.

Informational and educational content only. Not investment advice.